[Editorial] A New Era in Neurology

Why It Matters

These advances could dramatically reduce disability and health‑care costs, yet without scalable, equitable implementation the global neurological burden will keep rising.

Key Takeaways

• Biomarker‑driven definitions enable anti‑amyloid antibodies for Alzheimer’s
• Endovascular thrombectomy reshapes acute stroke treatment outcomes
• Over 20 disease‑modifying therapies now approved for multiple sclerosis
• Fluid tau biomarkers detect Alzheimer’s pathology decades before symptoms
• High treatment costs risk widening access disparities worldwide

Pulse Analysis

The past two decades have seen neurology evolve from a largely descriptive specialty to one grounded in molecular biology. Advances in genomics, high‑resolution neuroimaging, and fluid biomarkers now allow clinicians to define conditions such as Alzheimer’s disease by underlying pathology rather than clinical syndrome. This paradigm shift fuels more precise drug development, exemplified by anti‑amyloid monoclonal antibodies that target amyloid plaques identified through PET scans or plasma assays. The same biomarker momentum is reshaping stroke care, where rapid imaging guides endovascular thrombectomy, and multiple sclerosis, where over twenty disease‑modifying agents, including ocrelizumab, are now available.

Therapeutic innovation is being accelerated by smarter trial designs that leverage biomarkers for patient selection and endpoint measurement. Tau PET imaging, for instance, refines disease staging and predicts response to emerging Alzheimer’s therapies, while plasma phosphorylated tau (p‑tau217) can flag pathology in mid‑life, years before cognitive decline. These tools enable earlier intervention, a critical factor given the irreversible loss of neurons once disease progresses. Moreover, novel delivery platforms—such as receptor‑mediated transcytosis brain‑shuttle technologies—aim to overcome the blood‑brain barrier, expanding the pipeline of potentially disease‑modifying treatments.

Despite scientific momentum, the translation of these breakthroughs into routine care faces steep hurdles. High drug prices, the need for specialized laboratory infrastructure, and limited access to advanced imaging risk widening existing health disparities. Integrating biomarker‑driven diagnostics into primary‑care settings will demand coordinated workforce training, clear referral pathways, and substantial public‑private investment. Policymakers must prioritize equitable reimbursement models and infrastructure upgrades to ensure that the promise of a biologically informed neurology benefits all patients, not just those in well‑resourced health systems.